Minerva Neurosciences (United States)

Recent papers from Minerva Neurosciences (United States)

1. Cognitive decline in psychotic disorders: A longitudinal matched case-control studySchizophrenia Research Cognition · 2026
2. Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIESchizophrenia Research · 2026
3. Negative Symptoms in Schizophrenia: Methodological Challenges and Emerging Solutions for Outcome MeasurementNeuroscience Applied · 2026
4. In Vivo Studies of [ ¹⁶¹ Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2–Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth SuppressionJournal of Nuclear Medicine · 2026
5. Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve ThemAmerican Journal of Psychiatry · 2025
6. Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized TrialCNS Drugs · 2025
7. Efficacy and Safety of Seltorexant in Insomnia Disorder: A Randomized Clinical Trial.2025
8. A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluationNuclear Medicine and Biology · 2025
9. Roluperidone monotherapy, a treatment for negative symptoms in schizophreniaThe International Journal of Neuropsychopharmacology · 2025
10. Diversity in Naturally Acquired Immunity to Group B Streptococcus: A Comparative Study of Women From Bangladesh, Malawi, and the United KingdomThe Journal of Infectious Diseases · 2024
11. Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis RecurrenceSchizophrenia Bulletin · 2023
12. Toward a national eDNA strategy for the United StatesEnvironmental DNA · 2023
13. Long-term effects of Roluperidone on negative symptoms of schizophreniaSchizophrenia Research · 2023
14. Remote Assessment of Negative Symptoms of SchizophreniaCivil War Book Review · 2023
15. Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaSchizophrenia Bulletin · 2022
16. Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus StatementsSchizophrenia Bulletin Open · 2020
17. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorderTranslational Psychiatry · 2019
18. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomniaJournal of Psychopharmacology · 2019
19. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidityJournal of Psychopharmacology · 2018